Hikma Pharmaceuticals is a global pharmaceutical company with 29 manufacturing plants across the US, Europe, and MENA, producing injectable, oral, and respiratory medicines. The company offers CMO services and has announced a $1 billion investment by 2030 to expand US manufacturing and R&D capabilities. Hikma has 76 FDA-approved products, produces 500 million injectable units annually, and has maintained zero critical FDA observations in 20+ years.
sterile injectable manufacturing, oral solid dose, lyophilization, controlled substances, respiratory products (DPI/nasal), CMO services
10 sites worldwide
Involvement in 1 clinical trial
No reviews available yet.
No documents available.